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OBJECTIVES This study was undertaken to project the population-wide effect of full implementation of the
Adult Treatment Panel (ATP) II guidelines of the National Cholesterol Education Program
(NCEP).
BACKGROUND The ATP II has proposed guidelines for cholesterol reduction, but the long-term epidemi-
ologic influence of its components has not been fully examined.
METHODS We used a calibrated, validated simulation of the U.S. population, aged 35 to 84 years to
estimate the potential for the NCEP guidelines, under varying assumptions, to reduce
coronary heart disease morbidity and mortality and overall mortality from the years 2000 to
2020.
RESULTS Primary prevention would yield only about half of the benefits of secondary prevention despite
requiring nearly twice as many person-years of treatment. The projected increase in
quality-adjusted years of life per year of treatment for secondary prevention was 3- to 12-fold
higher than for primary prevention. To yield population-wide epidemiologic benefits
equivalent to NCEP recommendations for secondary prevention, primary prevention would
require a nearly sixfold increase in the number of persons treated compared with NCEP
recommendations. All benefits of universal success of the NCEP primary prevention “screen
and treat” guidelines could be achieved by a 11 mg/dl (8%) population-wide reduction in
low-density lipoprotein cholesterol levels among persons without preexisting coronary heart
disease.
CONCLUSIONS The NCEP guidelines for targeted primary prevention can be a useful component of a
rational public health strategy, but only as a complement to the more appealing strategies of
secondary prevention and “across-the-board” programs to lower all cholesterol levels. (J Am
Coll Cardiol 1999;34:768–76) © 1999 by the American College of Cardiology
The National Cholesterol Education Program (NCEP)
(1,2) clinical strategy guidelines for screening and treating
elevated cholesterol levels are rapidly becoming the standard
of care in the U.S. We and others (3–8) have previously
presented cost-effectiveness analyses indicating that choles-
terol reduction using medications becomes progressively
more attractive as the overall risk of coronary heart disease
events increases, and that secondary prevention is nearly
always more attractive than primary prevention from a
cost-effectiveness perspective. However, little attention has
been paid to the population-wide epidemiologic con-
siderations. Because many more people would be poten-
tially eligible for primary prevention of a first coronary
heart disease diagnosis than for secondary prevention
after their initial diagnosis, we analyzed the epidemio-
logic effect of the three different components of the
NCEP guidelines: secondary prevention, primary preven-
tion in higher-risk persons and primary prevention in
moderate-risk persons. We also analyzed the potential
incremental benefit of extending “diet-only” interven-
tions to more individuals, and our analyses considered
alternative scenarios.
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METHODS
The Coronary Heart Disease Policy Model (3,9–11) is a
Markov state-transition, computer-based model with three
integrated submodels: Demographic–Epidemiologic,
Bridge and Disease History. The model is based on the
assumption that categorized data from observational cohort
studies (12) are consistent with experimental clinical trials
(13–17) and can estimate the risk of coronary heart disease
events, and that ultimately such events influence mortality
(18).
The Demographic–Epidemiologic submodel applies to
the U.S. population aged 35 to 84 years without coronary
heart disease. Each year, a new cohort of 35-year-old
individuals (19,20) enters, and persons turning age 85 exit.
To exit before age 85, persons must die or develop coronary
heart disease, at which time they enter the Bridge submodel.
The Demographic–Epidemiologic submodel assesses
each individual’s risk of developing coronary heart disease
and death from all causes based on risk strata defined by age
(35 to 84 years in annual intervals), gender, smoking status
(yes or no), diastolic blood pressure (#94, 95–104 or
$105 mm Hg), serum cholesterol (#240 mg/dl [6.21 mmol/
L], 240–299 mg/dl [6.21–7.75 mmol/L] or .299 mg/dl
[7.75 mmol/L]), high-density lipoprotein (HDL) cholesterol
(,35 mg/dl [0.91 mmol/L], 35– 49 mg/dl [0.91–1.27
mmol/L] or .49 mg/dl [1.27 mmol/L]) and low-density
lipoprotein (LDL) cholesterol (,160 mg/dl [4.16 mmol/
L], 160–189 mg/dl [4.16–4.91 mmol/L] or .189 mg/dl
[4.9 mmol/L]). The initial multivariate distributions of risk
factors, conditional on age and gender, and transitions with
aging were modeled using data from the Second National
Health and Nutrition Examination Survey (NHANES II)
(21) and updated to reflect 1986 population averages based
on observed trends (22,23) and data from NHANES III
(24).
To predict the annual probability of a coronary heart
disease event or noncoronary heart disease death on the
basis of risk factors, multiple logistic risk functions that
controlled for all risk factors in the model simultaneously
and that allowed for interaction terms between risk factors
and age were estimated using 36-year follow-up data from
the Framingham Heart Study (25). The analysis assumed
that serum cholesterol did not affect noncoronary mortality
(13,14), but we also considered possible adverse effects in
sensitivity analyses. We assumed that the effect of risk factor
reduction on coronary mortality was mediated by its influ-
ence on coronary events (13–17). Coronary mortality and
overall mortality were derived from U.S. vital statistics (26).
The Bridge submodel characterizes participants as having
angina, myocardial infarction or cardiac arrest during the
first 30 days after they develop coronary heart disease, and
applies mortality probabilities and 30-day resource costs to
persons in each group (9). The Disease History submodel
tracks subsequent coronary heart disease events (myocardial
infarction, coronary revascularization and cardiac arrest),
case-fatality rates and resource costs in persons with prev-
alent coronary heart disease who survive the Bridge sub-
model or who enter the model at age 35 with preexisting
coronary heart disease.
Implementation of NCEP guidelines. The guidelines of
the Adult Treatment Panel II of the NCEP for dietary and
drug treatment of LDL cholesterol call for secondary
prevention to reduce LDL to 100 mg/dl, aggressive primary
prevention with a goal of 130 mg/dl for some patients (“goal
130”) and less demanding primary prevention with a goal of
160 mg/dl for other patients. We assumed all persons would
meet the stated goals either with diet or medications as
needed beginning at age 35 and continuing to age 84. The
target population for secondary prevention includes all
persons with clinical evidence of coronary heart disease,
with subjective guidelines for including persons with coro-
nary heart disease and low LDL levels (100 to 129 mg/dl).
The more aggressive primary prevention (which we term
“high-risk”) targets the population free of coronary heart
disease but with medium (160–189 mg/dl) or high (.189
mg/dl) LDL and a net of two or more additional coronary
heart disease risk factors, where age ($45 for men and $55
for women), smoking, hypertension, low HDL (,35 mg/
dl), family history of premature coronary heart disease and
diabetes mellitus are each positive risk factors, and high
HDL (.60 mg/dl) is a negative (protective) factor. The less
demanding primary prevention (which we term “medium-
risk”) targets persons with high LDL and at most one
additional risk factor. Additional categories of persons are
identified as candidates for “diet-only” intervention.
In our simulations, the target population for secondary
prevention was assumed to be all persons with coronary
heart disease. For primary prevention, simulations included
all NCEP risk factors, except that we could not specifically
identify persons with a family history of premature coronary
heart disease or diabetes mellitus. The NCEP guidelines
were simulated by decreasing the mean LDL level for each
cell in the model that corresponded to the target population
to the specified goal for that population.
Outcome measures included myocardial infarction, coro-
nary heart disease death, years of life and quality-adjusted
years of life. Quality of life adjustments using time trade-off
utility weights were calculated for persons with a history of
coronary heart disease (10,27). All simulations were for the
21-year period from 2000 to 2020.
Abbreviations and Acronyms
ATP 5 Adult Treatment Plan
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
NCEP 5 National Cholesterol Education Program
NHANES 5 National Health and Nutrition
Examination Survey
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Variations on model assumptions. In alternative simula-
tions, an association between cholesterol and noncoronary
heart disease death was estimated based on the natural
logarithm of serum cholesterol using pooled data from
several studies (28,29). We also implemented a modified
version of the NCEP guidelines in which high-risk and
medium-risk persons free of coronary heart disease were
treated with as aggressive an LDL goal as the population
with coronary heart disease.
In other analyses, we assumed that the NCEP guidelines
for dietary intervention alone, i.e., without follow-up drug
intervention, would be implemented for: 1) persons with
medium LDL (160–190 mg/dl) and at most one additional
coronary heart disease risk factor; and 2) persons with low
LDL (130–160 mg/dl) and at least two additional coronary
heart disease risk factors, and that a 10% reduction in LDL
could be realized. Our model does not have a separate
subcategory for LDL between 130 and 160 mg/dl, but we
estimated from NHANES data that the population with
two coronary heart disease risk factors and LDL in this
range is roughly half (41% for men, 52% for women) of the
population of persons with LDL less than 160 mg/dl, and
made our estimates accordingly.
RESULTS
If the Adult Treatment Panel II (ATP) recommendations
of the NCEP were followed to achieve the desired choles-
terol goals over the 21-year period from the year 2000 to
2020 in adults 35 to 84-years-old, there would be about 500
million person-years of treatment, with an average of about
11.5 million (48%) women and 12.5 million (52%) men
treated each year. About two-thirds of the years of treat-
ment are estimated to be for primary prevention, while
secondary prevention would be projected to account for only
about one-third of the overall person-years of treatment.
Impact of treatment. In women, the 26% of treatment
years for secondary prevention are projected to yield 59% of
the overall decrease in myocardial infarctions, 78% of the
decrease in coronary heart disease deaths, 80% of the
increase in years of life and 77% of the increase in quality-
adjusted years of life (Table 1). The projected increase in
quality-adjusted years of life per year of treatment was more
than 5.5-fold higher for secondary prevention than for
high-risk primary prevention and nearly 12-fold higher for
secondary prevention compared with medium-risk primary
prevention.
In men, the 42% of the person-years of treatment
allocated toward secondary prevention was estimated to
yield 60% of the decrease in myocardial infarctions, 76% of
the decrease in coronary heart disease deaths, 78% of the
increase in years of life and 75% of the increase in quality-
adjusted years of life (Table 2). Overall, secondary preven-
tion yielded projected increases in quality-adjusted years of
life per person-year of treatment that were more than
threefold higher than for high-risk primary prevention and
nearly sixfold higher than for medium-risk primary preven-
tion.
Age considerations. Across all ages among both men and
women, secondary prevention provided about 60% to 80%
of the additional years of life and quality-adjusted years of
life after the institution of treatment estimated to be
obtained from following the ATP II guidelines (Fig. 1). For
the population as a whole, however, the projected percent
increase in expected quality-adjusted years of life after the
institution of treatment was generally small, and was more
than 4% only among men over age 65 and women over age
75 (Fig. 2).
The percent change in years of life increases for age
ranges 45 to 54 and older due to the cumulative effect of
lives saved by intervention in younger ages. For example, by
2020, 75- to 84-year-old men and women have estimated
increases in years of life of 3.3% and 2.3%, respectively. By
2020, 65- to 74-year-old men have a projected 1.6%
additional years of life. All other age ranges have less than a
Table 1. Impact of NCEP Guidelines on Women (2000–2020)
Total
Number
Secondary
Prevention Only
High-Risk Primary
Prevention
(incremental impact
over secondary only)
Medium-Risk
Primary Prevention
(incremental impact
over high risk
1 secondary)
Number
% of
Total Number
% of
Total Number
% of
Total
Person-years of treatment 246,175,000 63,657,000 26% 39,372,000 16% 143,147,000 58%
Decrease in MIs 798,000 471,000 59% 119,000 15% 208,000 26%
Decrease in CHD deaths 800,000 625,000 78% 65,000 8% 110,000 14%
Increase in years of life 6,661,000 5,318,000 80% 489,000 7% 854,000 13%
Increase in quality adjusted life-years 6,628,000 5,109,000 77% 556,000 8% 963,000 15%
Increase in quality adjusted life-years
per person-year of treatment
0.0269 0.0803 0.0141 0.0067
CHD 5 coronary heart disease; MI 5 myocardial infarction; NCEP 5 National Cholesterol Education Program.
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1% increase. In contrast, for the absolute number of myo-
cardial infarctions and coronary heart disease deaths, the
cumulative effect is in the reverse direction, because persons
who would now survive to an older age are at risk for
myocardial infarctions and coronary heart disease death,
even if at a reduced rate. Thus, although all age ranges have
a projected decrease in rates of myocardial infarction and
coronary heart disease death, the absolute number of these
events is projected to increase in ages 55 to 64 and 65 to 74.
Absolute benefit of treatment. In the secondary treatment
of women, the projected additional quality-adjusted years of
life per person-year of treatment ranged from 8 per 1,000
for women ages 35 to 44 to nearly 140 per 1,000 for women
ages 75 to 84 (Table 3). In comparison, for medium-risk
primary prevention, the estimated yield was about 2 quality-
adjusted years of life per 1,000 years of treatment for women
ages 35 to 44, rising to 28 per 1,000 years of treatment for
women ages 75 to 84. Trends in men were analogous but
less dramatic (Table 3).
These estimates of differential effects are not surprising
given the very different baseline risks. The annualized risk of
coronary heart disease death in women who already have
coronary heart disease is 10% to 130% higher than those of
high-risk and medium-risk women without coronary heart
disease who are 30 years older (Fig. 3). Similarly, men who
already have coronary heart disease also have risks that are
15% to 50% higher than those of high-risk men without
coronary heart disease who are 30 years older (Fig. 4).
Annualized risks for myocardial infarction follow similar
patterns.
Aggressiveness of treatment. The greater influence of
secondary prevention is related in part to the more aggres-
sive goal of LDL cholesterol reduction for secondary pre-
vention (100 mg/dl) than for high-risk primary prevention
Table 2. Impact of NCEP Guidelines on Men (2000–2020)
Total
Number
Secondary Prevention
Only
High-Risk Primary
Prevention
(incremental impact
over secondary only)
Medium-Risk
Primary Prevention
(incremental impact
over high risk
1 secondary)
Number
% of
Total Number
% of
Total Number
% of
Total
Person-years of treatment 262,872,000 109,448,000 42% 89,034,000 34% 64,390,000 24%
Decrease in MIs 1,167,000 699,000 60% 330,000 28% 139,000 12%
Decrease in CHD deaths 925,000 702,000 76% 157,000 17% 66,000 7%
Increase in years of life 7,296,000 5,703,000 78% 1,113,000 15% 480,000 7%
Increase in quality adjusted life-years 7,296,000 5,467,000 75% 1,283,000 18% 546,000 7%
Increase in quality adjusted life-years
per person-year of treatment
0.0278 0.0500 0.0144 0.0085
CHD 5 coronary heart disease; MI 5 myocardial infarction; NCEP 5 National Cholesterol Education Program.
Figure 1. Additional quality-adjusted years of life (2000–2020). The shaded bar is for secondary intervention, the white bar is for
secondary plus high-risk primary interventions and the black bar is for secondary and high-risk primary plus medium-risk primary
intervention. The added years in each age range reflect the effects of the intervention in this age range as well as the delayed effects of
intervention in earlier ages.
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(130 mg/dl) or medium-risk primary prevention (160 mg/
dl). However, even if all three groups were treated to reduce
their LDL cholesterol levels to 100 mg/dl, about 50% of the
reduction in coronary heart disease deaths in both women
and men would be due to secondary prevention, although
only about 4% of the years of treatment of women and 7%
of the years of treatment in men would be for secondary
prevention. To achieve the aggressive goals, about 68
million medium-risk women and 47 million medium-risk
men would need to be treated annually, and the estimated
total number of treated persons would be increased by nearly
sixfold compared with NCEP recommendations.
Alternative primary prevention strategies. The influence
of the Adult Treatment Panel II recommendations for
primary prevention of coronary heart disease would be the
equivalent of the results achieved by an 8% (11 mg/dl)
reduction in LDL cholesterol in persons without coronary
heart disease. Alternatively, an 8-mm Hg decrease in
diastolic blood pressure or an 18% decrease in smoking rates
in persons without coronary heart disease would save about
the same number of quality-adjusted years of life.
Influence of including “diet-only” subjects. If “diet-only”
individuals are included in primary prevention, the number
of person-years of treatment roughly doubles. Even in the
unlikely event that dietary interventions would reduce LDL
cholesterol by 10%, at least half of the decrease in myocar-
dial infarctions as well as two-thirds of the decrease in
coronary heart disease deaths and the increases in years of
life and quality-adjusted years of life would be attributable
to secondary prevention, although only 15% of the person-
years of treatment would be for secondary prevention.
Possible noncoronary heart disease effects of cholesterol
reduction. If the noncoronary heart disease death rate
increased because of adverse effects of cholesterol lowering,
the benefits of cholesterol reduction would be blunted by an
average of about 11,000 more noncoronary deaths per year.
Nevertheless, years of life and quality-adjusted years of life
were still estimated to increase in every age range for both
men and women by about 80% to 90% of what would be
predicted without adverse effects on noncoronary mortality.
The incremental years of life gained by cholesterol reduction
would be less blunted in secondary prevention than in
primary prevention, and estimates of the relative benefit of
interventions would be even more in favor of secondary
prevention.
Table 3. Incremental Quality-adjusted Years of Life per 1,000 Person-Years of Treatment (2000–2020)
Treated Age
Range (yr)
Women Men
Secondary
Only
High Risk
(increment over
secondary only)
Medium Risk
(increment over
secondary 1 high risk)
Secondary
Only
High Risk
(increment over
secondary only)
Medium Risk
(increment over
secondary 1 high risk)
35–44 8 0 2 18 4 2
45–54 27 5 2 33 9 6
55–64 46 9 5 43 16 12
65–74 73 19 13 52 22 16
75–84 139 39 28 82 35 23
Quality-adjusted years of life gained per person-year of treatment for each level of intervention are shown for each age range/gender group.
Figure 2. Additional quality-adjusted years of life as a percent of person-years of treatment (2000–2020). The added quality-adjusted years
of life (from Fig. 1) are displayed here as a percent of person-years of treatment.
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Altering HDL criteria. Of persons with HDL .50 mg/dl,
about 60% of men and 45% of women have HDL levels
,60 mg/dl, and hence do not meet NCEP ATP II criteria
for a protective HDL level. However, even if we assumed
that all people with HDL .50 mg/dl would be eligible for
treatment under the NCEP ATP II guidelines, the propor-
tion of population-wide benefit attributable to primary
prevention would increase by only about one percentage
point in men and two percentage points in women, and
conclusions regarding the relative influence of primary
versus secondary prevention were not appreciably affected by
our use of an HDL cutoff of 50 mg/dl.
DISCUSSION
We do not dispute the role of LDL cholesterol as a risk
factor, HDL cholesterol as a protective factor, or the
benefits of medications for improving lipid levels and
reducing coronary heart disease events, coronary heart
disease mortality or overall mortality (1,13–18,30). Of note
is that the CHD Policy Model has been accurate in previous
predictions (31,32), but we cannot guarantee future predic-
tions. Our model could not include diabetes or a positive
family history of premature coronary heart disease, and its
specifications required that we model an HDL threshold
of .50 mg/dl, rather than .60 mg/dl, as a protective factor.
These limitations led to some underestimation of the
number of persons eligible for primary prevention, but a
sensitivity analysis suggests that any effect on our estimates
of the population-wide influence of primary prevention is
very minor. Furthermore, our estimate of the number of
Americans eligible for secondary prevention is also on the
lower side of the various estimates (33), and any increase in
persons eligible for secondary prevention would only rein-
force our conclusions.
Figure 3. Annualized risk per 1,000 of coronary heart disease (CHD) death for women (2000–2020). Baseline values represent the risk
to the population in the category if no intervention is implemented for that group. Postintervention values give the risk if NCEP guidelines
are implemented as described in the text.
Figure 4. Annualized risk per 1,000 of coronary heart disease (CHD) death for men (2000–2020). Baseline values represent the risk to
the population in the category if no intervention is implemented for that group. Postintervention values give the risk if NCEP guidelines
are implemented as described in the text.
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Our analyses emphasize that under a wide variety of
assumptions, 60% to 75% of the population-wide epidemi-
ologic benefit of cholesterol reduction potentially achievable
from the ATP II guidelines would be in secondary preven-
tion. These analyses demonstrate that the segment of the
population for which cholesterol reduction is the most
cost-effective on a per-person basis (3–8) is also the segment
that is likely to realize about two-thirds of overall benefits.
Our estimates were remarkably consistent, were similar
for women and men, and were of reasonably similar relative
effect across various age groups. Even much more aggressive
treatment goals or the inclusion of a “diet-only” intervention
in a much larger number of persons would have only a small
effect on the relative epidemiologic importance of secondary
as compared with primary prevention despite the inclusion
of far greater numbers of persons in a primary prevention
intervention.
The guidelines of the ATP of the NCEP (1) emphasize
a case-finding strategy, sometimes called “screen and treat,”
analogous to the very successful approach to diagnosing and
treating hypertension (34). This approach to hypertension is
widely credited with achieving substantial populationwide
reductions in blood pressure and stroke (35) and is clearly
worth the cost (36), mostly because screening can be
performed inexpensively during routine health visits.
For population-wide “screen and treat” programs for
cholesterol reduction, however, the challenge is more com-
plicated. Effective classification may require multiple blood
tests, and these tests must be repeated to assess treatment
efficacy. Furthermore, current medications are generally
more costly on an annual basis than medications to control
hypertension, and it is not surprising that cost-effectiveness
estimates for primary prevention have generally been far less
favorable for hypercholesterolemia than for hypertension.
Prior concerns regarding the ATP II guidelines have
focused on the potential adverse effects of lowering choles-
terol (37), the current cost of medications (38) and the
practicality of screening, classifying and appropriately treat-
ing the entire population (39), but we are less concerned
with these three issues. First, recent data suggest that fears
regarding the adverse effects of lowering cholesterol were at
least exaggerated if not unfounded (13–18,30). Second,
concerns about cost-effectiveness can be addressed by low-
ering the cost of medications, which represent most of the
costs of implementing the ATP II guidelines. Third, al-
though recent surveys estimate that only 1 in 12 adults is
being screened annually (39) and that more than 50% of
hypercholesterolemic U.S. citizens remain unaware of their
elevated cholesterol levels (40), such logistic hurdles could
be overcome if the recommended strategy is truly the most
appropriate route to solving a major public health problem.
In addition, cholesterol reduction likely reduces stroke (41),
a noncoronary heart disease benefit that is often overlooked
in economic analyses.
However, even if the ATP II guidelines were followed
perfectly nationwide, about two-thirds of the influence
would come from secondary prevention, where costs per
benefit are lower (41) and the likelihood of implementation
by physicians and compliance by patients is far higher.
Although not directly modeled, the stroke benefit of cho-
lesterol reduction would also likely be largest in persons with
more advanced atherosclerosis and other evidence for cor-
onary heart disease, thereby being consistent with our
estimate of the relatively greater influence of secondary as
compared with primary prevention. Second, the population-
wide influence of perfect implementation of the ATP II
guidelines for primary prevention in persons without coro-
nary heart disease would be roughly equivalent to an 8% (11
mg/dl) reduction in LDL cholesterol in these same persons.
Reductions of this magnitude (about 13–14 mg/dl in total
cholesterol) have been achieved over the last decade or so
(42–44), without an appreciable reliance on medications or
systematic changes in the food supply. Of course, it is
unlikely that any “screen and treat” strategy will ever be
successful to its full potential epidemiologic influence
(45,46). Interventions across the population, such as immu-
nization, fluoridation or even dietary changes (2,46), as
suggested by the Population Strategy Panel of the NCEP
(47) and by others, are as or are more likely to succeed
compared with more complicated approaches that require
targeted screening, treatment and compliance.
A successful public health program for the prevention of
coronary heart disease via lipid lowering should emphasize
secondary prevention with diet and medications. Primary
prevention with approaches such as dietary changes that do
not require individual measurement of cholesterol levels
(2,48) are also extremely appealing. Targeted “screen and
treat” primary prevention based on the ATP II guidelines
can also be very useful and can be cost-effective for especially
high-risk patients without clinical coronary heart disease,
but should not be misinterpreted as the principal strategy for
maximizing public health effects (49,50). Because a substan-
tial proportion of coronary heart disease deaths occur in
previously asymptomatic persons, the development of cost-
effective primary prevention strategies must remain a high
public health priority.
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